baloxavir marboxil (Xofluza)
Jump to navigation
Jump to search
Indications
* about as effective as oseltamivir (may be better)[2]
* must be taken within 2 days of exposure
Contraindications
- CDC does not recommend use of baloxavir for treatment of influenza in pregnant women, breastfeeding mothers, or immunosuppressed persons[7]
Dosage
tablets
granules for mixing in water
Pharmacokinetics
- faster reduction of viral levels & viral shedding than oseltamivir, but little difference in alleviating symptoms
Drug interactions
- should not be co-administered foods/beverages/supplements containing calcium, iron, magnesium, selenium, aluminum or zinc.
Mechanism of action
- cap-dependent endonuclease inhibitor
More general terms
References
- ↑ Smith M, North American Correspondent. Investigational Flu Drug a Near Match for Oseltamivir - Clinical outcomes 'identical' but virology different. MedPage Today. October 08, 2017 https://www.medpagetoday.com/MeetingCoverage/IDWeek/68407
- ↑ 2.0 2.1 Hayden FG, Sugaya N, Hirotsu N Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med 2018; 379:913-923. Sept 6, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30184455 https://www.nejm.org/doi/full/10.1056/NEJMoa1716197
- ↑ Brooks M FDA OKs Xofluza, First New Flu Antiviral in Nearly 20 Years. Medscape - Oct 24, 2018. https://www.medscape.com/viewarticle/903911
FDA News Release. Oct 24, 2018 FDA approves new drug to treat influenza. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm624226.htm - ↑ Brooks M FDA Expands Xofluza Indication to People at High-Risk for Flu Complications Medscape - Oct 17, 2019. https://www.medscape.com/viewarticle/920030
- ↑ Ikematsu H et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med 2020 Jul 23; 383:309. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32640124 https://www.nejm.org/doi/10.1056/NEJMoa1915341
Uyeki TM. Baloxavir for postexposure prophylaxis against influenza in households. N Engl J Med 2020 Jul 23; 383:389 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32640147 https://www.nejm.org/doi/10.1056/NEJMe2022702 - ↑ FDA News Release. Nov 23, 2020 FDA Expands Approval of Influenza Treatment to Post-Exposure Prevention. https://www.fda.gov/news-events/press-announcements/fda-expands-approval-influenza-treatment-post-exposure-prevention
- ↑ 7.0 7.1 Bronze MS Fast Five Quiz: Influenza Practice Essentials Medscape. November 3, 2021 https://reference.medscape.com/viewarticle/962197
Nguyen HH, Bronze MS Influenza Treatment & Management Medscape. November 5, 2021 https://emedicine.medscape.com/article/219557-treatment